同时准BCL-xL与MCL-1诱导扩散性半导体瘤的致死性功能障碍
Yuan Xu1, Cristian G Medina1, Deborah R Surman2
1David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery and the Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Molecular cancer therapeutics
|September 4, 2025
概括
向MCL-1,而不是同时向BCL- xL和MCL-1,可以提高扩散性间皮瘤的化疗效果. 这种方法降低了亡值,并改善了模型中无毒性的化学敏感性.
科学领域:
- 癌症学
- 分子生物学
- 癌症治疗方法
背景情况:
- 扩散性间皮瘤是一种具有有限治疗选择和高耐药性的侵袭性癌症.
- 通过抑制亡,抗亡蛋白MCL- 1和BCL- xL有助于治疗耐药性.
- 了解耐药机制对于开发有效的间皮瘤治疗至关重要.
研究的目的:
- 在不同间皮瘤模型中研究B细胞同质域3配置文件的一致性.
- 评估MCL-1和BCL-xL在扩散性间皮瘤中的有效性.
- 确定扩散性间皮瘤的安全有效治疗策略.
主要方法:
- 用B细胞同源域3分析来比较瘤样本,来自患者的细胞和异种移植.
- 在体外研究中评估了BCL- xL和MCL- 1共同向对细胞活力和细胞亡的影响.
- 在患者衍生的异种移植 (PDX) 中的体内研究评估了向这些蛋白质的治疗潜力.
主要成果:
- 在患者内部模型中,B细胞同质域3的概况一致,使得可以进行跨模型比较.
- 同时向BCL- xL和MCL- 1显示出对细胞活力降低和细胞亡增加的协同作用.
- 在体内共同向导致PDX模型中的合成致死性,这表明临床开发缺乏安全性.
- 单独向MCL-1降低了亡值,增强了化学敏感性,并且在PDX模型中没有显示出毒性.
结论:
- 单独向MCL-1是一种潜在的安全策略,可以提高扩散性间皮瘤的化疗效果.
- 由于合成致死性,同时向BCL-xL和MCL-1并不是一种安全的临床方法.
- 未来的临床策略应侧重于抑制MCL-1,以克服间皮瘤的治疗阻力.
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
01:31The Intrinsic Apoptotic Pathway
6.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.8K
01:46Electron Transport Chain: Complex I and II
15.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.0K